Circulating fibroblast growth factor 23 in children on peritoneal dialysis is associated with effective dialysis

Area of Science:

• Pediatric Nephrology
• Endocrinology
• Cardiovascular Research

Background:

• Fibroblast growth factor 23 (FGF23) is implicated in mineral metabolism and cardiovascular health.
• Children on peritoneal dialysis (PD) face complex metabolic and cardiovascular challenges.
• Understanding FGF23 dynamics in pediatric PD patients is crucial for managing their health.

Purpose of the Study:

• To investigate the relationship between serum FGF23 and cardiovascular parameters (left ventricular function, carotid intima-media thickness) in pediatric PD patients.
• To explore the association of serum FGF23 with key laboratory markers, including mineral metabolism and dialysis adequacy.

Main Methods:

• Cross-sectional study involving 17 pediatric patients on PD.
• Assessment of serum FGF23, phosphorus, calcium, intact parathyroid hormone (iPTH), vitamin D metabolites (25(OH)D, 1,25(OH)2D), and dialysis adequacy (Kt/V urea).
• Evaluation of left ventricular mass (LVM) and index (LVMI).

Main Results:

• Serum FGF23 levels were significantly and independently associated with Kt/V urea (p<0.001).
• Median FGF23 level was 29.92 pg/ml, with elevated iPTH (438 pg/ml) and low 25(OH) vitamin D (11 ng/ml).
• No significant association was reported between FGF23 and left ventricular parameters or CIMT in this cohort.

Conclusions:

• Effective dialysis, as measured by Kt/V urea, appears to be the primary determinant of FGF23 levels in pediatric PD patients.
• The calcium-phosphorus-PTH axis may play a less dominant role in regulating FGF23 in this specific population.
• Further research is warranted to elucidate the long-term cardiovascular implications of FGF23 levels in children on PD.